Lydie Trautmann

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3837977/publications.pdf

Version: 2024-02-01

34	4,569	361413	395702
papers	citations	20 h-index	33 g-index

35	35	35	6023
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. Journal of Clinical Investigation, 2022, 132, .	8.2	9
2	The ingenol-based protein kinase C agonist GSK445A is a potent inducer of HIV and SIV RNA transcription. PLoS Pathogens, 2022, 18, e1010245.	4.7	11
3	Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection. JAMA - Journal of the American Medical Association, 2022, 327, 179.	7.4	89
4	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. Journal of Immunology, 2022, 208, 54-62.	0.8	16
5	Transforming dysfunctional CD8+ T cells into natural controllerâ€“like CD8+ T cells: can TCF-1 be the magic wand?. Journal of Clinical Investigation, 2022, 132, .	8.2	1
6	CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies. Current Opinion in HIV and AIDS, 2022, 17, 315-324.	3.8	10
7	Transcriptional and Immunologic Correlates of Response to Pandemic Influenza Vaccine in Aviremic, HIV-Infected Children. Frontiers in Immunology, 2021, 12, 639358.	4.8	2
8	Activation of the Anti-Oxidative Stress Response Reactivates Latent HIV-1 Through the Mitochondrial Antiviral Signaling Protein Isoform MiniMAVS. Frontiers in Immunology, 2021, 12, 682182.	4.8	3
9	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. Journal of Virus Eradication, 2020, 6, 100004.	0.5	23
10	Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner. Frontiers in Immunology, 2020, 11, 1430.	4.8	7
11	Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection. Science Translational Medicine, 2020, 12, .	12.4	69
12	CTL Clonotypes with Higher TCR Affinity Have Better Ability to Reduce the HIV Latent Reservoir. Journal of Immunology, 2020, 205, 699-707.	0.8	7
13	Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption. Journal of Clinical Investigation, 2020, 130, 2845-2858.	8.2	31
14	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. Journal of Clinical Investigation, 2020, 130, 3299-3304.	8.2	24
15	Resistance to the Tat Inhibitor Didehydro-Cortistatin A Is Mediated by Heightened Basal HIV-1 Transcription. MBio, 2019, 10, .	4.1	38
16	Role of T Lymphocytes in HIV Neuropathogenesis. Current HIV/AIDS Reports, 2019, 16, 236-243.	3.1	15
17	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	4.7	73
18	Modeling HIV-1 Latency Using Primary CD4⁺T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy. Journal of Virology, 2019, 93, .	3.4	9

#	Article	IF	Citations
19	Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. Journal of Infectious Diseases, 2018, 218, 1453-1463.	4.0	28
20	Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nature Medicine, 2018, 24, 923-926.	30.7	263
21	Lymphoid tissue fibrosis is associated with impaired vaccine responses. Journal of Clinical Investigation, 2018, 128, 2763-2773.	8.2	55
22	Delayed differentiation of potent effector CD8 ⁺ T cells reducing viremia and reservoir seeding in acute HIV infection. Science Translational Medicine, 2017, 9, .	12.4	95
23	T Cell Immunity and Zika Virus Vaccine Development. Trends in Immunology, 2017, 38, 594-605.	6.8	32
24	High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 108-117.	2.1	31
25	InÂVivo Suppression of HIV Rebound by Didehydro-Cortistatin A, a â€œBlock-and-Lockâ€•Strategy for HIV-1 Treatment. Cell Reports, 2017, 21, 600-611.	6.4	189
26	Kill. Current Opinion in HIV and AIDS, 2016, 11, 409-416.	3.8	24
27	Altered Memory Circulating T Follicular Helper-B Cell Interaction in Early Acute HIV Infection. PLoS Pathogens, 2016, 12, e1005777.	4.7	37
28	The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency. MBio, 2015, 6, e00465.	4.1	188
29	Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. Journal of Clinical Investigation, 2014, 124, 3147-3158.	8.2	168
30	Clonotype and Repertoire Changes Drive the Functional Improvement of HIV-Specific CD8 T Cell Populations under Conditions of Limited Antigenic Stimulation. Journal of Immunology, 2012, 188, 1156-1167.	0.8	38
31	Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood, 2012, 120, 3466-3477.	1.4	70
32	Ex vivo measurement of the cytotoxic capacity of human primary antigen-specific CD8 T cells. Journal of Immunological Methods, 2012, 375, 252-257.	1.4	17
33	HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nature Medicine, 2009, 15, 893-900.	30.7	1,519
34	Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine, 2006, 12, 1198-1202.	30.7	1,376